Generation of a chemical genetic model for JAK3
Abstract Janus Kinases (JAKs) have emerged as an important drug target for the treatment of a number of immune disorders due to the central role that they play in cytokine signalling. 4 isoforms of JAKs exist in mammalian cells and the ideal isoform profile of a JAK inhibitor has been the subject of...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-89356-4 |
id |
doaj-66b7f58af7964f179690d10510378958 |
---|---|
record_format |
Article |
spelling |
doaj-66b7f58af7964f179690d105103789582021-05-16T11:23:22ZengNature Publishing GroupScientific Reports2045-23222021-05-0111111310.1038/s41598-021-89356-4Generation of a chemical genetic model for JAK3Judit Remenyi0Rangeetha Jayaprakash Naik1Jinhua Wang2Momchil Razsolkov3Alyssa Verano4Quan Cai5Li Tan6Rachel Toth7Samantha Raggett8Carla Baillie9Ryan Traynor10C. James Hastie11Nathanael S. Gray12J. Simon C. Arthur13Division of Cell Signalling and Immunology, School of Life Sciences, Wellcome Trust Building, University of DundeeDivision of Cell Signalling and Immunology, School of Life Sciences, Wellcome Trust Building, University of DundeeDepartment of Cancer Biology, Dana Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical SchoolDivision of Cell Signalling and Immunology, School of Life Sciences, Wellcome Trust Building, University of DundeeDepartment of Cancer Biology, Dana Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical SchoolDepartment of Cancer Biology, Dana Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical SchoolDepartment of Cancer Biology, Dana Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical SchoolMRC PPU Reagents and Services, School of Life Sciences, University of DundeeMRC PPU Reagents and Services, School of Life Sciences, University of DundeeMRC PPU Reagents and Services, School of Life Sciences, University of DundeeMRC PPU Reagents and Services, School of Life Sciences, University of DundeeMRC PPU Reagents and Services, School of Life Sciences, University of DundeeDepartment of Cancer Biology, Dana Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical SchoolDivision of Cell Signalling and Immunology, School of Life Sciences, Wellcome Trust Building, University of DundeeAbstract Janus Kinases (JAKs) have emerged as an important drug target for the treatment of a number of immune disorders due to the central role that they play in cytokine signalling. 4 isoforms of JAKs exist in mammalian cells and the ideal isoform profile of a JAK inhibitor has been the subject of much debate. JAK3 has been proposed as an ideal target due to its expression being largely restricted to the immune system and its requirement for signalling by cytokine receptors using the common γ-chain. Unlike other JAKs, JAK3 possesses a cysteine in its ATP binding pocket and this has allowed the design of isoform selective covalent JAK3 inhibitors targeting this residue. We report here that mutating this cysteine to serine does not prevent JAK3 catalytic activity but does greatly increase the IC50 for covalent JAK3 inhibitors. Mice with a Cys905Ser knockin mutation in the endogenous JAK3 gene are viable and show no apparent welfare issues. Cells from these mice show normal STAT phosphorylation in response to JAK3 dependent cytokines but are resistant to the effects of covalent JAK3 inhibitors. These mice therefore provide a chemical-genetic model to study JAK3 function.https://doi.org/10.1038/s41598-021-89356-4 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Judit Remenyi Rangeetha Jayaprakash Naik Jinhua Wang Momchil Razsolkov Alyssa Verano Quan Cai Li Tan Rachel Toth Samantha Raggett Carla Baillie Ryan Traynor C. James Hastie Nathanael S. Gray J. Simon C. Arthur |
spellingShingle |
Judit Remenyi Rangeetha Jayaprakash Naik Jinhua Wang Momchil Razsolkov Alyssa Verano Quan Cai Li Tan Rachel Toth Samantha Raggett Carla Baillie Ryan Traynor C. James Hastie Nathanael S. Gray J. Simon C. Arthur Generation of a chemical genetic model for JAK3 Scientific Reports |
author_facet |
Judit Remenyi Rangeetha Jayaprakash Naik Jinhua Wang Momchil Razsolkov Alyssa Verano Quan Cai Li Tan Rachel Toth Samantha Raggett Carla Baillie Ryan Traynor C. James Hastie Nathanael S. Gray J. Simon C. Arthur |
author_sort |
Judit Remenyi |
title |
Generation of a chemical genetic model for JAK3 |
title_short |
Generation of a chemical genetic model for JAK3 |
title_full |
Generation of a chemical genetic model for JAK3 |
title_fullStr |
Generation of a chemical genetic model for JAK3 |
title_full_unstemmed |
Generation of a chemical genetic model for JAK3 |
title_sort |
generation of a chemical genetic model for jak3 |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-05-01 |
description |
Abstract Janus Kinases (JAKs) have emerged as an important drug target for the treatment of a number of immune disorders due to the central role that they play in cytokine signalling. 4 isoforms of JAKs exist in mammalian cells and the ideal isoform profile of a JAK inhibitor has been the subject of much debate. JAK3 has been proposed as an ideal target due to its expression being largely restricted to the immune system and its requirement for signalling by cytokine receptors using the common γ-chain. Unlike other JAKs, JAK3 possesses a cysteine in its ATP binding pocket and this has allowed the design of isoform selective covalent JAK3 inhibitors targeting this residue. We report here that mutating this cysteine to serine does not prevent JAK3 catalytic activity but does greatly increase the IC50 for covalent JAK3 inhibitors. Mice with a Cys905Ser knockin mutation in the endogenous JAK3 gene are viable and show no apparent welfare issues. Cells from these mice show normal STAT phosphorylation in response to JAK3 dependent cytokines but are resistant to the effects of covalent JAK3 inhibitors. These mice therefore provide a chemical-genetic model to study JAK3 function. |
url |
https://doi.org/10.1038/s41598-021-89356-4 |
work_keys_str_mv |
AT juditremenyi generationofachemicalgeneticmodelforjak3 AT rangeethajayaprakashnaik generationofachemicalgeneticmodelforjak3 AT jinhuawang generationofachemicalgeneticmodelforjak3 AT momchilrazsolkov generationofachemicalgeneticmodelforjak3 AT alyssaverano generationofachemicalgeneticmodelforjak3 AT quancai generationofachemicalgeneticmodelforjak3 AT litan generationofachemicalgeneticmodelforjak3 AT racheltoth generationofachemicalgeneticmodelforjak3 AT samantharaggett generationofachemicalgeneticmodelforjak3 AT carlabaillie generationofachemicalgeneticmodelforjak3 AT ryantraynor generationofachemicalgeneticmodelforjak3 AT cjameshastie generationofachemicalgeneticmodelforjak3 AT nathanaelsgray generationofachemicalgeneticmodelforjak3 AT jsimoncarthur generationofachemicalgeneticmodelforjak3 |
_version_ |
1721439482342801408 |